Economic implications of rasburicase treatment in adult patients with tumour lysis syndrome

Eaddy M, Seal B, Tangirala K, Davies EH, O'Day K

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
23013428

DOI
10.2165/11634230-000000000-00000

Original Paper URL
http://adisonline.com/healtheconomics/pages/articleviewer.aspx?year=2012&amp;issue=10060&amp;article=00008&amp;type=abstract

Indexing Status
Subject indexing assigned by NLM

MeSH
Adult; Aged; Aged, 80 and over; Allopurinol /economics /therapeutic use; Cohort Studies; Drug Therapy, Combination; Female; Gout Suppressants /economics /therapeutic use; Hospitalization /economics /statistics & numerical data; Humans; Length of Stay /economics /statistics & numerical data; Linear Models; Male; Middle Aged; Propensity Score; Retrospective Studies; Time Factors; Tumor Lysis Syndrome /drug therapy /economics; Urate Oxidase /economics /therapeutic use

AccessionNumber
22012042805

Date bibliographic record published
09/01/2013